Literature DB >> 35142053

Deep residual inception encoder-decoder network for amyloid PET harmonization.

Jay Shah1,2, Fei Gao1,2, Baoxin Li1,2, Valentina Ghisays3, Ji Luo3, Yinghua Chen3, Wendy Lee3, Yuxiang Zhou4, Tammie L S Benzinger5, Eric M Reiman3, Kewei Chen3, Yi Su1,2,3, Teresa Wu1,2.   

Abstract

INTRODUCTION: Multiple positron emission tomography (PET) tracers are available for amyloid imaging, posing a significant challenge to consensus interpretation and quantitative analysis. We accordingly developed and validated a deep learning model as a harmonization strategy.
METHOD: A Residual Inception Encoder-Decoder Neural Network was developed to harmonize images between amyloid PET image pairs made with Pittsburgh Compound-B and florbetapir tracers. The model was trained using a dataset with 92 subjects with 10-fold cross validation and its generalizability was further examined using an independent external dataset of 46 subjects.
RESULTS: Significantly stronger between-tracer correlations (P < .001) were observed after harmonization for both global amyloid burden indices and voxel-wise measurements in the training cohort and the external testing cohort. DISCUSSION: We proposed and validated a novel encoder-decoder based deep model to harmonize amyloid PET imaging data from different tracers. Further investigation is ongoing to improve the model and apply to additional tracers.
© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Entities:  

Keywords:  Alzheimer's disease; Centiloid; amyloid PET

Year:  2022        PMID: 35142053      PMCID: PMC9360199          DOI: 10.1002/alz.12564

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   16.655


  40 in total

1.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

Review 2.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

Authors:  Justin M Long; David M Holtzman
Journal:  Cell       Date:  2019-09-26       Impact factor: 41.582

3.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

Authors:  Henryk Barthel; Hermann-Josef Gertz; Stefan Dresel; Oliver Peters; Peter Bartenstein; Katharina Buerger; Florian Hiemeyer; Sabine M Wittemer-Rump; John Seibyl; Cornelia Reininger; Osama Sabri
Journal:  Lancet Neurol       Date:  2011-04-08       Impact factor: 44.182

4.  Partial volume correction in quantitative amyloid imaging.

Authors:  Yi Su; Tyler M Blazey; Abraham Z Snyder; Marcus E Raichle; Daniel S Marcus; Beau M Ances; Randall J Bateman; Nigel J Cairns; Patricia Aldea; Lisa Cash; Jon J Christensen; Karl Friedrichsen; Russ C Hornbeck; Angela M Farrar; Christopher J Owen; Richard Mayeux; Adam M Brickman; William Klunk; Julie C Price; Paul M Thompson; Bernadino Ghetti; Andrew J Saykin; Reisa A Sperling; Keith A Johnson; Peter R Schofield; Virginia Buckles; John C Morris; Tammie L S Benzinger
Journal:  Neuroimage       Date:  2014-12-05       Impact factor: 6.556

5.  Automated (11)C-PiB standardized uptake value ratio.

Authors:  Parnesh Raniga; Pierrick Bourgeat; Jurgen Fripp; Oscar Acosta; Victor L Villemagne; Christopher Rowe; Colin L Masters; Gareth Jones; Graeme O'Keefe; Olivier Salvado; Sébastien Ourselin
Journal:  Acad Radiol       Date:  2008-11       Impact factor: 3.173

6.  Reducing between scanner differences in multi-center PET studies.

Authors:  Aniket Joshi; Robert A Koeppe; Jeffrey A Fessler
Journal:  Neuroimage       Date:  2009-02-06       Impact factor: 6.556

7.  Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.

Authors:  Adam S Fleisher; Kewei Chen; Yakeel T Quiroz; Laura J Jakimovich; Madelyn Gutierrez Gomez; Carolyn M Langois; Jessica B S Langbaum; Napatkamon Ayutyanont; Auttawut Roontiva; Pradeep Thiyyagura; Wendy Lee; Hua Mo; Liliana Lopez; Sonia Moreno; Natalia Acosta-Baena; Margarita Giraldo; Gloria Garcia; Rebecca A Reiman; Matthew J Huentelman; Kenneth S Kosik; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  Lancet Neurol       Date:  2012-11-06       Impact factor: 44.182

8.  Predicting Alzheimer's disease progression using multi-modal deep learning approach.

Authors:  Garam Lee; Kwangsik Nho; Byungkon Kang; Kyung-Ah Sohn; Dokyoon Kim
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

9.  Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease.

Authors:  Sanka Amadoru; Vincent Doré; Catriona A McLean; Fairlie Hinton; Claire E Shepherd; Glenda M Halliday; Cristian E Leyton; Paul A Yates; John R Hodges; Colin L Masters; Victor L Villemagne; Christopher C Rowe
Journal:  Alzheimers Res Ther       Date:  2020-03-04       Impact factor: 6.982

10.  Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies.

Authors:  Yi Su; Shaney Flores; Russ C Hornbeck; Benjamin Speidel; Andrei G Vlassenko; Brian A Gordon; Robert A Koeppe; William E Klunk; Chengjie Xiong; John C Morris; Tammie L S Benzinger
Journal:  Neuroimage Clin       Date:  2018-04-25       Impact factor: 4.881

View more
  1 in total

1.  β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3.

Authors:  Pierrick Bourgeat; Vincent Doré; Samantha C Burnham; Tammie Benzinger; Duygu Tosun; Shenpeng Li; Manu Goyal; Pamela LaMontagne; Liang Jin; Christopher C Rowe; Michael W Weiner; John C Morris; Colin L Masters; Jurgen Fripp; Victor L Villemagne
Journal:  Neuroimage       Date:  2022-07-30       Impact factor: 7.400

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.